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ARTICLE
Deficiency for the Ubiquitin Ligase UBE3B
in a Blepharophimosis-Ptosis-Intellectual-Disability
Syndrome
Lina Basel-Vanagaite,1,2,3,4,* Bruno Dallapiccola,5 Ramiro Ramirez-Solis,6 Alexandra Segref,7,8
Holger Thiele,9 Andrew Edwards,10,22 Mark J. Arends,11 Xavier Miró,12 Jacqueline K. White,6
Julie Désir,13,23 Marc Abramowicz,13,14 Maria Lisa Dentici,5 Francesca Lepri,5 Kay Hofmann,7,15
Adi Har-Zahav,2 Edward Ryder,6 Natasha A. Karp,6 Jeanne Estabel,6 Anna-Karin B. Gerdin,6
Christine Podrini,6 Neil J. Ingham,6 Janine Altmüller,9 Gudrun Nürnberg,9 Peter Frommolt,8,9
Sonia Abdelhak,16 Metsada Pasmanik-Chor,17 Osnat Konen,2,18 Richard I. Kelley,19
Mordechai Shohat,1,2,3 Peter Nürnberg,8,9,20 Jonathan Flint,10 Karen P. Steel,6 Thorsten Hoppe,7,8
Christian Kubisch,21 David J. Adams,6 and Guntram Borck21,*
Ubiquitination plays a crucial role in neurodevelopment as exemplified by Angelman syndrome, which is caused by genetic alterations
of the ubiquitin ligase-encoding UBE3A gene. Although the function of UBE3A has been widely studied, little is known about its paralog
UBE3B. By using exome and capillary sequencing, we here identify biallelic UBE3Bmutations in four patients from three unrelated fami-
lies presenting an autosomal-recessive blepharophimosis-ptosis-intellectual-disability syndrome characterized by developmental delay,
growth retardation with a small head circumference, facial dysmorphisms, and low cholesterol levels. UBE3B encodes an uncharacter-
ized E3 ubiquitin ligase. The identified UBE3B variants include one frameshift and two splice-site mutations as well as a missense substi-
tution affecting the highly conserved HECT domain. Disruption of mouse Ube3b leads to reduced viability and recapitulates key aspects
of the human disorder, such as reduced weight and brain size and a downregulation of cholesterol synthesis. We establish that the prob-
able Caenorhabditis elegans ortholog of UBE3B, oxi-1, functions in the ubiquitin/proteasome system in vivo and is especially required
under oxidative stress conditions. Our data reveal the pleiotropic effects of UBE3B deficiency and reinforce the physiological importance
of ubiquitination in neuronal development and function in mammals.Introduction
Ubiquitination is a posttranslational protein modification
that plays a key role in brain development. The ubiqui-
tin/proteasome system (UPS) degrades damaged proteins
and is part of the cellular protein quality control
network.1–3 Polyubiquitination involves the sequential
transfer of the 76 amino acid protein ubiquitin between
a ubiquitin-activating enzyme (E1), a ubiquitin-conju-
gating enzyme (E2), and a ubiquitin ligase (E3). The speci-
ficity of this complex process is mainly determined by the
E3 ligase, of which more than 600 are encoded in the
human genome.4 HECT domain E3 ligases constitute
a major group of E3 enzymes5 that not only are involved
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of specific receptors, channels, and transporters.6 Ubiquiti-
nation is involved in both gliogenesis and neurogenesis
through its influence on cellular signaling cascades such
as the Notch and Hedgehog pathways.1 Ubiquitination
thereby contributes to regulating neuronal migration,
neuritogenesis, and the formation and elimination of
synapses. Consequently, alterations of the UPS can
engender neuronal dysfunction and lead to neurological
disease and intellectual disability (ID).2
A prototype disorder involving altered ubiquitination is
the human neurodevelopmental disease Angelman syn-
drome (MIM 105830). Angelman syndrome is character-
ized by ID, speech delay, gait ataxia, and a characteristic
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seizures.7 It is caused by mutations of the imprinted gene
UBE3A (MIM 601623), which encodes the HECT domain-
containing ubiquitin ligase E3A. Although some of the
clinical signs of Angelman syndromemight be due to ubiq-
uitin-independent functions of UBE3A, recent studies
suggest that altered ubiquitination of synaptic proteins
such as Arc and Ephexin5 contributes to the cognitive
dysfunction that occurs in Angelman syndrome.8,9
Furthermore, maternal 15q duplications encompassing
UBE3A lead to a predisposition for autism spectrum disor-
ders, and an increased copy number of Ube3a may confer
autism-related behaviors in mice,10,11 pointing to an
important role of UBE3A gene dosage in brain develop-
ment and function.
The application of classical and high-throughput genetic
technologies has recently led to the identification of a large
number of genes involved in the pathogenesis of nonsyn-
dromic and syndromic forms of ID,12–14 and this approach
has also been applied to the blepharophimosis-mental
retardation (BMR) syndromes, with mutations of the
histone acetyltransferase gene KAT6B (MIM 605880)
causing the autosomal-dominant Say-Barber/Biesecker/
Young-Simpson (SBBYS) type of Ohdo syndrome (MIM
603736).15 The clinically and genetically heterogeneous
BMR or Ohdo-like syndromes16–19 (MIM 249620) are char-
acterized—in addition to developmental delay and ID—by
blepharophimosis, a narrowing and shortening of the
palpebral fissures, and various congenital anomalies.
Here, we have identified and characterized mutations of
UBE3B (MIM 608047) in an ID syndrome of this clinical
spectrum and we show that disruption of mouse Ube3b
phenocopies some aspects of the human disorder.Subjects and Methods
Subjects
The research project on the genetics of ID syndromes was per-
formed with approval by the ethics committees of the Rabin
Medical Center (Petah Tikva, Israel) and the University of Ulm
(Ulm, Germany). Subjects were enrolled with parental written
informed consent to participate in the study. DNA was extracted
according to standard protocols.
Exome Sequencing
Genomic DNA was enriched for exonic and adjacent splice site
sequences with the Agilent SureSelect Human All Exon 50 Mb
kit and libraries were run on three lanes of the Illumina Genome
Analyzer IIX Sequencer via the single end read 150 bp protocol.
Further data analysis of the resulting filter-passed reads was per-
formed with the in-house pipeline V1.4 with BWA-short20 in
combination with SAMTOOLS 0.1.7 for SNP and indel detec-
tion.21 In-house developed scripts were applied to detect protein
changes, affected splice sites, and overlaps to known variations
(ENSEMBL build 61, 1000 Genomes project release 2010_03, in-
house variation database containing >100 exomes). We searched
for stretches of homozygosity by using SNPs (excluding indels)
with a Phred score >100 and a coverage of >20-fold, and SNPs
with an allele frequency >85% were considered homozygous.The AmericanSanger Sequencing Validation and SNP Array
Genotyping
Validation of variants detected by exome sequencing was per-
formed by Sanger sequencing. Primer sequences are listed in Table
S1 available online. PCR products were sequenced on an ABI
3730 DNA Analyzer with BigDye chemistry v3.1 (Applied Bio-
systems). Sequence traces were assembled, aligned, and analyzed
with the Seqman software (DNASTAR Lasergene). Mutation
nomenclature is based on GenBank transcript NM_130466.2,
which contains 28 exons; the start codon is located in exon 3.
DNA of 100 anonymous control individuals each of Israeli-
Arab and Italian origin were tested for the relevant mutation(s)
by direct sequencing. DNA from patient 4 and her parents was
genotyped on an Affymetrix GeneChip Human Mapping 250K
Nsp Array.
RT-PCR
Total RNA from peripheral white blood cells of affected individuals
and controls was extracted from fresh EDTA blood by a standard
trizol protocol. RT-PCR was performed with the QIAGEN OneStep
RT-PCR kit with primers UBE3B-RT-PCR-F1 50-TTGGAATGCCT
GAACAATGA-30 and UBE3B-RT-PCR-R1 50-TGGAAGAGCACGC
TAGGTTT-30 (for the c.1741þ2T>C mutation) and UBE3B-RT-
PCR-F2 50-GTATGTGTCCCTGGCTTGTTC-30 and UBE3B-RT-PCR-
R2 50-ATCACGGCATCGATCTTGGTC-30 (for the c.5452A>G
mutation). PCR products were cut out from a 2% agarose gel and
directly sequenced after purification.
3D Structural Analysis
To assess the potential functional consequences of the
p.Gln727Pro substitution, the HECT domain of UBE3B was
modeled to several structurally characterized HECT domains,
including the HECT domain of SMURF2,22 by using the PHYRE2
server.23
Analysis of Protein Degradation in C. elegans
Caenorhabditis elegans strains were maintained according to
standard procedures and grown at 20C.24 The strain PP563
unc-119(ed4)III; hhIs64 [unc-119(þ); sur-5::UbV-GFP]III was used
for analysis.
RNA interference was performed via the feeding method.25 The
oxi-1 RNAi clone was obtained from the Ahringer RNAi library26
and the empty feeding vector was used as a control. Worms were
applied at the L4 larval stage on standard RNAi plates with or
without addition of paraquat (Sigma) and analyzed for the expres-
sion of GFP after 24 hr at 20C.
Worms were treated with RNAi on control or oxi-1 RNAi plates
without the addition of paraquat. qRT-PCR was performed as
previously described.27
Worms were imaged under a Leica M165 FC stereomicroscope
equipped with a Leica DFC 340 FX camera and handled with the
Leica LAS V3.4.0 analysis software. Images were processed with
Adobe Photoshop CS 4 software for figure assembly.
Immunoblotting was performed as previously described.27
Mouse In Situ Hybridization
Part of the Ube3b mRNA (nucleotides 3,666–4,464 of GenBank
transcript NM_054093) was amplified from murine postnatal
day (P) 46 brain cDNA. The PCR product was then cloned into
the pCRII-TOPO vector (Invitrogen) and the insert was sequence
verified. In situ hybridizations were performed on whole embryoJournal of Human Genetics 91, 998–1010, December 7, 2012 999
sections at embryonic day (E) 12.5 and E14.5 and on brain (E16.5,
P9, and P24) and head (P0) sections as previously described.28Generation of Ube3b Genetrap Mice
Mutant mice were generated through blastocyst injection of
mutant embryonic stem cells (ESCs) obtained from the Interna-
tional Gene Trap consortium; specifically BayGenomics gene trap
ESC clone RRJ142 (129P2/OlaHsd). Chimeric mice were bred to
CBA/Ca females, and the colony was expanded and maintained
by intercrossing; control mice were wild-type littermates. Thus,
these studies were carried out on a 129P2/Ola 3 CBA/Ca mixed
genetic background. The strain has been deposited at the European
Mutant Mouse Archive (EM:04922). Analyses were performed
retrospectively on data generated by the Mouse Genetics Project
at the Wellcome Trust Sanger Institute. The gene trap vector is in-
serted upstream of the majority of the exons encoding the HECT
domain. Genotyping was performed by PCR on ear clip lysate to
detect the wild-type (50-CGGCACGTTCCACTGTCCC-30 and 50-
TGCCAGCCCCACCAGCATC-30; 664 bp) and mutant alleles (50-
CGGCACGTTCCACTGTCCC-30 and 50-GCACGCCATACAGTCCT
CTTC-30; 470 bp), as well as the E. coli lacZ cassette present in the
gene trap vector (50-ATCACGACGCGCTGTATC-30 and 50-ACAT
CGGGCAAATAATATCG-30; 108 bp). Cycling conditions for the
wild-type and mutant PCRs were 94C 5 min; 353 (94C 30 s,
58C 30 s, 72C 45 s); 72C 5 min. For lacZ, the same conditions
were used except the annealing temperature was shifted to 60C.
We verified absence of Ube3b mRNA in Ube3b/ mice by qRT-
PCR. Frozen skin (pinnae) samples were homogenized and RNA
was extracted with a QIAGEN fibrous tissue extraction kit. 1 ml
(~100–200 ng) of total RNAwas used in a 10 ml reactionwith a Taq-
Man RNA-to-CT One Step kit (Applied Biosystems). A TaqMan
probe spanning exons 19–20 of Ube3b, flanking the gene trap
insertion point (Applied Biosystems probe Mm00459868_m1),
was used in a multiplex reaction with either a primer-limited
B2m or a Gapdh endogenous control (Applied Biosystems). Reac-
tions were performed in triplicate on an ABI Viia7 qPCR machine
and analyzed with Viia7 1.1 software, with the relative quantifica-
tion module. Reactions performed with the Gapdh endogenous
probe gave a higher variation within the technical replicates
than with the B2m probe. No Ube3b expression was detected
with either endogenous control assay.Mouse Phenotypic Analysis
Animals
The care and use of all mice in this study were in accordance with
the UK Home Office regulations, UK Animals (Scientific Proce-
dures) Act of 1986. Mice were bred and maintained in a specific-
pathogen-free unit, room temperature and humidity regulated
(21C 5 2C; 55% 5 10%), and 12/12 hr light/dark cycle with
lights off at 19:30 hr and no twilight period. Mice were housed
in individually ventilated cages (IVC) (Techniplast Seal Safe
1284L) receiving 60 air changes per hour, at a stocking density
of 3–5 mice per cage (floor area ¼ 530 cm2). Aspen bedding
substrate and standard environmental enrichment of nestlet, card-
board tunnel, and three wooden chew blocks were provided. Mice
were given water and breeding diet (5021, Labdiet) ad libitum.
Phenotyping
Female mice were weighed weekly between 9 and 14 weeks of age.
At 9 weeks of age, grip strength was assessed (Bioseb grip strength
meter). Three trials each of forepaws and all paws were performed
in succession. Representative data are presented (all-paw trial 1). At1000 The American Journal of Human Genetics 91, 998–1010, Decem14weeks of age, nonfastedmice were terminally anesthetized with
Avertin (1.25% 2,2,2-Tribromoethanol, Sigma Aldrich) and blood
was collected via the retro-orbital sinus into lithium/heparin-
coated tubes. After centrifugation (5,0003 g, 10min, 8C), plasma
was analyzed for low-density lipoprotein concentration with an
Olympus AU400. After the terminal bleed, tissues were fixed in
4% paraformaldehyde, processed through to paraffin, and
sectioned (5 mm). An automatic slide stainer (Leica ST5020) was
used to generate hematoxylin and eosin (H&E)-stained sections
of the eyes and brain. 14-week-old mice fed on high-fat diet
(Western RD, 829100, Special Diets Services) from 4 weeks of age
were anesthetized and high-resolution digital X-ray images were
acquired with a MX20 (Faxitron X-ray Corporation). Brains from
two 6-week-old male Ube3b/ mice and nine age-, gender-, and
background-matched controls were perfusion fixed in 4% PFA.
Prior to sectioning, brains were placed in 30% sucrose/PBS
solution for 24 hr. Brains were then sectioned coronally at
40 mm on a sliding microtome. Matched sections were mounted
on electrostatic slides, Nissl stained, and digitally scanned to
computer on an Epson V750 pro scanner at 6400 dpi. ImageJ free-
ware was subsequently used to take measurements of total brain
section area, hippocampus area, and dentate gyrus length. To
avoid introduction of bias, experimenters were blind to the
genotype of the mice during all procedures. Furthermore, cages
were processed randomly and different genotypes housed
together. Auditory brainstem response (ABR) thresholds were re-
corded in anesthetized mice via subcutaneous pin electrodes on
the head as described previously.29 Averaged ABR waveforms
to broad-band clicks and tonepips presented in 3 dB steps
were examined to determine the lowest intensity to give a recog-
nizable response. After ABR, mice were culled, middle ears were
opened and examined, and inner ears were removed, cleared,
and examined.
Numbers of homozygous (Ube3b/; Hom), heterozygous
(Ube3bþ/; Het) and WT mice used in the different phenotypic
analyses are as follows: weight: 7 Hom, 15 Het, 9 WT; grip
strength: 7 Hom, 15 Het, 9 WT; LDL cholesterol: 5 Hom, 14 Het,
4 WT; brain section area: 2 Hom, 0 Het, 9 WT; hippocampus
area: 2 Hom, 0 Het, 9 WT; length of the dentate gyrus: 2 Hom,
0 Het, 9 WT; ABR at 3 months: 7 Hom, 10 Het, 14 WT; ABR at
6 months: 6 Hom, 7 Het, 9 WT; survival at 2 weeks: 31 Hom,
263 Het, 124 WT.
Statistical Methods
For the comparison of growth curves, statistical significance—in
terms of differences in the rate of growth between the three geno-
types—was assessed via the CompareGrowthCurve function of the
statmod software package for R. The initial p values were adjusted
for multiple testing by Holm’s method. For the comparison of LDL
levels and grip strength, a mixed model data analysis was
completed with a six step top-down methodology to build the
final model as detailed in West et al.30 The process starts with
a two level random intercept mixed model with assay date as
a random effect and genotype, sex, body weight, and genotype*
sex interaction term as fixed effects. Within the six step procedure,
a 0.05 significance threshold was used to assess the output of the
hypothesis testing. ABR thresholds were significantly raised in
homozygotes compared with wild-types via either the Kruskall
Wallis ANOVA on ranks (p < 0.001) or Dunn’s method of multiple
comparisons. Differences in brain section and hippocampus areas
and the length of the dentate gyrus were assessed with t tests per-
formed in R.ber 7, 2012
Figure 1. A Blepharophimosis-Ptosis-
Intellectual-Disability Syndrome
(A–D) Individual 1 at the age of 1 year (A),
individual 2 at the age of 7 years 7 months
(B), individual 3 at the age of 3 years
1 month (C), and individual 4 at the age
of 1 year 2 months (D). Note characteristic
facial features with blepharophimosis and
ptosis, sparse hair, sparse and arched
eyebrows, long philtrum, anteverted nares,
retrognathia, and low-set, posteriorly
rotated ears. Individuals 2 and 3 also have
upslanting palpebral fissures; this feature
develops with age.
(E) Cranial MRI scan of individual 1 (Ind.
1) at age 1 year 10months shows cerebellar
tonsillar ectopia consistent with Chiari 1
malformation, thin corpus callosum, and
an overall small head. A cranial MRI scan
of a healthy age-matched control (Co) is
also shown.Results
Clinical Delineation of an Intellectual-Disability
Syndrome
We initially studied three individuals from two unrelated
families with an apparently identical BMR syndrome
(Supplemental Data). Individual 1 from family 1 (Figures
1A and S1, Table 1) was a girl born to unaffected parents
of Israeli-Arab origin who are first cousins. We noted
a striking facial similarity and overlapping clinical features
with the previously reported female andmale siblings from
family 2 (individuals 2 and 3, respectively; Figures 1B, 1C,
and S1, Table 1)19 in which the unaffected parents of
Italian descent are not consanguineous. Common clinical
signs noted in the three affected individuals included char-
acteristic facial dysmorphisms with blepharophimosis,
ptosis, and mild upslanting of the palpebral fissures and
epicanthus (Figures 1A–1C); ectodermal anomalies; devel-
opmental delay; and severe ID with absent speech (Supple-
mental Data). Proportionate growth retardation with
a small head circumference/microcephaly, congenital mal-
formations, muscular hypotonia, and anomalies on brain
imaging with hypoplasia of the corpus callosum
(Figure 1E) were variably present (Table 1). We refer to
this syndrome as a blepharophimosis-ptosis-intellectual-
disability (BPID) syndrome belonging to the heterogenous
group of BMR syndromes.
Routine biochemical serum analysis revealed that HDL
cholesterol was low in individual 1, and low total choles-
terol was noted in individual 2, suggesting that a defect
in cholesterol metabolism might be part of the syndrome.
We therefore performed mass spectrometry-based analysis
of patient serum samples, which showed a consistent
downregulation of cholesterol synthesis in the threeThe American Journal of Human Genetipatients, including a low lathosterol/
total sterol ratio (lathosterol/total
sterol ratio in patients versus controls0.46). In conclusion, the autosomal-recessive BPID
syndrome affecting individuals 1–3 represents a clinically
recognizable neurodevelopmental disorder.16,19
Exome Sequencing Identifies Truncating UBE3B
Mutations
We sequenced the exomes of unrelated individuals 1 and 2
on an Illumina platform after enrichment of exonic and
splice-site sequences. We mapped reads to the hg19
human reference genome and obtained a mean coverage
of 124-fold for both subjects. Approximately 90% of target
sequences were covered at least ten times (Table S2).
We observed no mutation in KAT6B, a gene recently
shown to be mutated in the majority of the patients with
the autosomal-dominant SBBYS type of Ohdo syn-
drome.15 Because of parental consanguinity in family 1
and the lack of consanguinity in family 2 and assuming
an autosomal-recessive inheritance pattern and genetic
homogeneity, we searched for a gene harboring a rare
homozygous variant in individual 1 and rare compound
heterozygous variants in individual 2. We considered vari-
ants if they were not annotated as single-nucleotide poly-
morphisms (SNPs) in dbSNP132, the 1000 Genomes data,
and our in-house exome database and focused onmissense,
nonsense, small insertion/deletion, and splice site variants.
We identified 29 autosomal regions of extended homozy-
gosity in individual 1 (Table S3). Sixteen genes mapping
to these regions harbored a rare homozygous nonsynony-
mous or splice site variant in individual 1 (Figure S2).
Only 1 of these 16 genes, however, UBE3B, also carried
two distinct rare variants in individual 2, consistent with
compound heterozygous mutations. Thus, UBE3B was the
only genewith rare or unique biallelic damagingmutations
observed in both affected individuals.cs 91, 998–1010, December 7, 2012 1001
Table 1. Clinical, Radiological, and Biochemical Features of Individuals with Biallelic UBE3B Mutations
Family 1 Family 2 Family 3
Individual 1 Individual 2 Individual 3 Individual 4
Origin Israel Italy Tunisia
Parental consanguinity þ (first cousins) - - þ (first cousins)
Sex F F M F
Pregnancy/Neonatal Period
Oligohydramnios - - þ -
Respiratory problems stridor due to laryngomalacia apnea - stridor due to laryngomalacia
Feeding difficulties/GER þ (þ) (improved at 5 years) þ þ
Frequent infections recurrent otitis media - recurrent bronchitis
until 1 year
recurrent respiratory
infections
Growth
Failure to thrive þ þ þ þ
Short stature - þ þ þ
Microcephaly þ þ þ þ
Motor and Cognitive Development
Delayed motor milestones þ þ þ þ
Absent speech þ (3 years 3 months) þ (7 years 7 months) þ (3 years 1 month) þ (17 months)
Severe intellectual disability þ þ þ severe developmental delay
Craniofacial
Blepharophimosis þ þ þ þ
Ptosis þ þ (left) - þ
Upward-slanting
palpebral fissures
- þ þ -
Telecanthus þ þ þ þ
Hypertelorism - þ þ þ
Depressed nasal bridge þ þ þ þ
Anteverted nares þ þ þ þ
Low-set/dysplastic ears þ þ þ þ
Palatal anomalies high arched palate þ (submucous cleft palate) - -
Micrognathia þ þ þ þ
Small mouth þ þ þ þ
Neurological
Abnormal brain image chiari type I malformation,
ventricular dilatation,
hypoplastic CC
agenesis of the
CC rostrum, anterior
commissure not evident
reduced size of the
pituitary gland, partial
empty sella
hypoplastic CC
Axial hypotonia þ þ - þ
Ocular impairment þ (astigmatism) þ (astigmatism, mild
strabism, and myopia)
- -
Hearing impairment þ (conductive) - - -
Ectodermal Anomalies
Sparse thin hair/eyebrows þ þ þ þ
Eczema - - þ -
Thin skin þ þ þ þ
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Table 1. Continued
Family 1 Family 2 Family 3
Individual 1 Individual 2 Individual 3 Individual 4
Cardiac
Congenital heart disease þ (ASD, VSD, aortic
coarctation)
- - þ (ASD)
Gastrointestinal
Gastrectasia - þ - -
Constipation - (þ) (resolved at 6y) þ -
Distension of gall-bladder - þ - -
Intestinal malrotation þ - - -
Skeletal/Limb
Clinodactyly of 5th fingers - þ þ -
Congenital dislocation
of the hip
þ - - þ
Urogenital abnormalities mild left pyelectasis double right kidney,
right pyelectasis
- Hypoplastic labia majora
Endocrine and Laboratory Anomalies
Thyroid anomalies - elevated TSH (until
5 years) and reduced
thyroid gland volume
- -
Low growth hormone levels NA - þ NA
Low ACTH level NA - þ NA
Anomalies of cholesterol
levels
low HDL cholesterol low total cholesterol - low total cholesterol
Others severe hyperlaxity torticollis, delayed
bone age
- partial epilepsy
UBE3B mutation paternal
allele
c.1741þ2G>C c.5452A>G c.5452A>G c.2180A>C (p.Gln727Pro)
UBE3B mutation maternal
allele
c.1741þ2G>C c.2223_2224delAG
(p.Arg741Serfs*3)
c.2223_2224delAG
(p.Arg741Serfs*3)
c.2180A>C (p.Gln727Pro)
Abbreviations: ASD, atrial septal defect; CC, corpus callosum; GER, gastresophageal reflux; HDL, high-density lipoprotein; NA, not available/not performed; VSD,
ventricular septal defect.Confirmation and Characterization of BiallelicUBE3B
Mutations
We confirmed all three UBE3B mutations by capillary
(Sanger) sequencing. Individual 1 was homozygous for
a c.1741þ2T>C mutation (Figure 2A) affecting the
consensus splice donor site of exon 16. This mutation led
to skipping of exon 16 and—to a lesser extent—skipping
of exons 16 and 17 in RNAderived fromblood of individual
1 (Figure 2B). The parents were both heterozygous carriers
of this mutation. In family 2, both affected siblings
were compound heterozygous for a maternally inherited
2 bp deletion (c.2223_2224delAG [p.Arg741Serfs*3])
and a paternally inherited splice acceptor mutation
(c.5452A>G; Figure 2C). The lattermutation again caused
exon skipping, namely skipping of exon 8 and skipping of
exons 8 and 9 in RNA derived from blood of individual 2
(Figure 2D). All three UBE3B mutations introduce prema-
ture termination codons and are thus expected to resultThe American Join nonsense-mediated mRNA decay and/or protein trun-
cation. None of these mutations was present in 100 ethni-
cally matched control individuals as shown by sequencing
of the respective exons. The mutations were also not
present in ~7,000 European-American control alleles
sequenced by the NHLBI Exome Sequencing Project.31
UBE3B encodes the putative ubiquitin ligase E3B,
a protein of 1,068 amino acids that contains an N-terminal
IQ domain and a C-terminal HECT domain.32 HECT
domains are crucial for the function of E3 ubiquitin ligases
because they mediate both the binding of an E2 ubiquitin-
conjugating enzyme through their large N-terminal subdo-
main and the transfer of ubiquitin to the substrate, which
is mediated by the catalytic cysteine located in the small
C-terminal subdomain.6 The three UBE3B mutations we
report lead to protein truncation before or at the beginning
of the HECT domain (Figure 2E), thus presumably
completely abolishing the enzyme’s E3 ligase activity.urnal of Human Genetics 91, 998–1010, December 7, 2012 1003
Figure 2. UBE3B Mutations Cause the
BPID Syndrome
(A and B) Sequence chromatograms
showing the homozygous (MUT/MUT)
and heterozygous (WT/MUT) UBE3B splice
donor mutation c.1741þ2T>C identified
in family 1 (A) that leads to skipping of
exon 16 (119 bp; out-of-frame) and exons
16 and 17 (234 bp; in-frame) as shown by
RT-PCR on RNA extracted from whole
blood of individual 1 (B). Exon skipping
was confirmed by sequence analysis of
the respective RT-PCR products (not
shown).
(C and D) Individuals 2 and 3 are
compound heterozygotes for c.2223_
2224delAG and the splice acceptor muta-
tion c.5452A>G (C), the latter leading
to out-of-frame skipping of exon 8
(86 bp) and exons 8 and 9 (169 bp) as
shown by RT-PCR (D) and sequence anal-
ysis (not shown).
(E) Protein diagram of human UBE3B de-
picting the N-terminal IQ domain (short
calmodulin-binding motif containing
conserved Ile [I] and Gln [Q] residues)
and the C-terminal HECT (homologous
to the E6-AP carboxyl terminus) domain.
The positions of the three truncating mutations identified in individuals 1–3 are indicated by black arrows and the p.Gln727Pro
missense alteration is shown in red.
(F) Sequence chromatograms showing the homozygous (MUT/MUT) and heterozygous (WT/MUT) UBE3B missense alteration
p.Gln727Pro (c.2180A>C) identified in individual 4 andmultiple sequence alignment of UBE3B orthologs surrounding the Gln727 posi-
tion in the human protein.Identification of a Missense Substitution in the UBE3B
HECT Domain in an Additional Individual with BPID
Syndrome
To obtain additional evidence for the involvement of
UBE3B mutations in BMR syndromes, we sequenced the
gene in a girl (individual 4 from family 3; Figures 1D and
S1, Table 1) with a BMR syndrome characterized by short
stature, developmental delay, seizures, hypoplasia of the
corpus callosum, sparse hair, and thin skin. She had minor
facial dysmorphic features (Figure 1D), and the clinical
picture strongly suggested that she was affected by the
same BPID syndrome as individuals 1–3. In line with this
assumption, her total cholesterol was <100 mg/dl (which
is below the fifth centile for children and adolescents)
with relatively low lathosterol, comparable to the findings
in individuals 1–3. Individual 4 was born to unaffected
parents of Tunisian ancestry who are first cousins, suggest-
ing that a causative mutation would be present in the
homozygous state. By sequencing the coding exons of
UBE3B, we indeed detected a homozygous mutation,
c.2180A>C, that was predicted to lead to a substitution of
a highly conserved glutamine by proline (p.Gln727Pro;
Figure 2F). Both parents were heterozygous mutation
carriers and themutationwas locatedwithin a35Mb region
of homozygosity (between rs2583147 and rs11059122) in
the proband as shown by genome-wide SNP array genotyp-
ing, consistent with a large region of homozygosity-by-
descent. The c.2180A>C mutation was absent from 100
Tunisian control individuals as ascertained by sequencing1004 The American Journal of Human Genetics 91, 998–1010, Decemof UBE3B exon 20. It was also not present in the ~10,000
alleles sequenced by the NHLBI Exome Sequencing Project.
Gln727 is located in the HECT domain of UBE3B and is
strictly conserved in orthologs from 41 species for which
Ube3b protein sequences are available at the UCSC
multiple species sequence alignment, including mouse,
chicken, zebrafish, the frog Xenopus tropicalis, and the
worm Caenorhabditis elegans (Figure 2F and data not
shown). Three-dimensional modeling of the UBE3B
HECT domain to several structurally characterized HECT
domains showed that the mutated Gln727 is not within
reach of the catalytic site but is on the same face of the
HECT domain (Figure S3) and might thus be involved in
substrate recognition and binding.
The C. elegans Ortholog of UBE3B Plays a Role in the
UPS under Conditions of Oxidative Stress
Although the primary protein sequence and domain archi-
tecture of UBE3B predict an E3 ligase function,32 experi-
mental support for this assumption is lacking and specific
ubiquitination targets of UBE3B have not been identified.
We used a C. elegans in vivo assay27 to investigate and char-
acterize a possible role of the orthologous gene oxi-1 in the
UPS. The protein sequences of human UBE3B and worm
OXI-1 are 37% identical and 58% similar overall and
62% identical in the HECT domain. Moreover, a phyloge-
netic analysis shows that OXI-1 is more closely related to
human UBE3B than to UBE3A and UBE3C (Figure S4A),
suggesting that OXI-1 represents the species ortholog ofber 7, 2012
Figure 3. oxi-1, the Caenorhabditis
elegans Ortholog of UBE3B, Is Involved in
Ubiquitin/Proteasome-Mediated Protein
Turnover In Vivo
(A) Immunoblot of lysates derived from
worms after control (ctrl) RNAi or RNAi
against oxi-1 or hecd-1.
(B) Immunoblot of lysates derived from
worms after control or oxi-1 RNAi without
(0) or with addition of 0.5 or 1 mM para-
quat. The blot was performed with a GFP-
specific antibody; tubulin serves as loading
control.
(C) Images of C. elegans that express the
UbV-GFP reporter to measure protein turn-
over. Worms were treated as in (B). Top,
transmitted light; bottom, GFP fluores-
cence. Scale bar represents 0.5 mm.UBE3B. oxi-1 was originally identified as an oxidative
stress-responsive gene because its expression is upregu-
lated under high-oxygen conditions.33
We used an engineered ubiquitin fusion degradation
(UFD) substrate in which a noncleavable ubiquitin is
N-terminally fused to GFP (UbV-GFP) and expressed under
the control of the sur-5 promoter to monitor protein degra-
dation in vivo.27 In adult wild-type worms, the UbV-GFP
protein is efficiently ubiquitinated and degraded by the
26S proteasome (see control RNAi in Figures 3A–3C).
RNAi-mediated knockdown of hecd-1, a well-studied E3
ligase-encoding gene, leads to an impairment of protein
degradation under basal conditions, as shown by a stabili-
zation of the UbV-GFP substrate in hecd-1 (RNAi)-treated
worms (Figure 3A). Knockdown of oxi-1 (Figure S4B) only
minimally affected the degradation of UbV-GFP under
basal conditions (Figures 3A–3C). Exposing wild-type
worms to low doses of the oxidative stress-inducing agent
paraquat resulted in stabilization of UbV-GFP, as shown by
GFP fluorescence and immunoblotting.27 Notably, para-
quat treatment led to a dose-dependent stronger stabiliza-
tion of the UbV-GFP substrate in oxi-1 (RNAi)-treated
worms in comparison to control RNAi (Figures 3B and
3C). Thus, the C. elegans ortholog of UBE3B is involved
in protein degradation by the UPS and might be especially
required under oxidative stress conditions.
Mouse Ube3b Is Expressed in the Central Nervous
System
To characterize the spatial and temporal expression pattern
of Ube3b, we performed in situ hybridizations of embry-
onic and postnatal mouse tissues, which revealed predom-
inant expression in distinct anatomical structures of the
developing central nervous system. These results confirm
and extend high-throughput data generated by GenePaint,
a digital atlas of gene expression patterns in the mouse.34The American Journal of Human GenetWe detected Ube3b expression from
embryonic day (E) 12.5 through
E16.5 in the ventricular zone of the
cerebral cortex (Figures 4A–4C) whereneuronal progenitor cells undergo asymmetric cell divi-
sions. Ube3b was also enriched at E12.5 in the cortical
hem (Figure 4A), the hippocampal anlage. Moreover, we
found Ube3b expression in the tectum (Figures 4A and
4B), the cortical plate (Figures 4B and 4C), the dorsal root
ganglia (Figure 4B), and the preoptic neuroepithelium
(Figure 4C). Interestingly, Ube3b expression was observed
in craniofacial structures, namely in the epithelium of
the medial nasal process (Figure 4A) and in the whiskers
(Figures 4B). Postnatally, we detected prominent Ube3b
expression in the upper layers of the cerebral cortex
(Figures 4D–4F), the cerebellum (Figures 4E and 4F), and
the hippocampus (Figure 4F). Taken together, Ube3b
expression in the central nervous system and in craniofa-
cial structures is consistent with the phenotypes observed
in individuals with UBE3B-deficient BPID syndrome.
Disruption of Mouse Ube3b Recapitulates Clinical
Aspects of the BPID Syndrome
To gain further insight into the consequences of UBE3B
deficiency on an organismal level, we analyzed a Ube3b
mutant mouse. Mice with a disrupted Ube3b locus were
generated with a BayGenomics genetrap clone carrying
the Ube3bGt(RRJ142)Byg allele and were maintained on a
129P2/Ola 3 CBA/Ca background. Phenotyping was con-
ducted at the Wellcome Trust Sanger Institute by the
Mouse Genetics Project (see the Sanger Mouse Resources
Portal in the Web Resources). The structure of the genetrap
allele was confirmed by 50-RACE and by mapping and
sequencing the genetrap integration site within a Ube3b
intron (data not shown). We confirmed by quantitative
PCR that Ube3b/ mice do not express detectable levels
of Ube3b mRNA (Figure S5).
Although some Ube3b/ mice were born from heterozy-
gous intercrosses, homozygotes represented only 7% of
offspring at 2 weeks (Figure S6A), which is significantlyics 91, 998–1010, December 7, 2012 1005
Figure 4. Expression Pattern of Ube3b in Mouse
In situ hybridization via a Ube3b antisense probe on sagittal (A, B,
D–F) and coronal (C) sections at embryonic (E) and postnatal (P)
days as indicated. Ch, cortical hem; Cp, cortical plate; Cx, cerebral
cortex; Dr, dorsal root ganglia; Eg, external granular layer; En,
epithelium of the medial nasal process; Gl, granular layer; Hi,
hippocampus; Ig, internal granular layer; Pn, preoptic neuroepi-
thelium; Te, tectum; Vz, ventricular zone; Wh, whiskers.below the expected Mendelian ratio (c2 test, p < 0.0001)
and indicates an elevated embryonic and/or perinatal
lethality. Surviving Ube3b/ mice could reproduce,
although poorly (data not shown). Ube3b/ mice had
severely reduced body weight (Figure 5A), small body size
(Figure 5B), and reduced brain section area (Figure 5C)
with reduced sizes of the hippocampus (Figure 5D) and
dentate gyrus (Figure S6B) but no obvious structural abnor-
malities on histopathological examination (Figure S6C).
The reduced brain section size and hippocampus area of
Ube3b/ mice might in part be related to their low weight
but this is unlikely to be the only reason. We verified this
by conducting Pearson correlation tests in a pool of 29
age- and sex-matched WT animals. We found that
although body weight correlated with brain weight (p <
0.05, r ¼ 0.4), body weight did not correlate with hippo-
campus area (p ¼ 0.274) or brain section area size (p ¼
0.267) in WT mice. Thus, Ube3b/ mice have anomalies
of brain size that may reflect the small head circumfer-
ence/microcephaly seen in affected individuals with the
BPID syndrome caused by UBE3B mutations.1006 The American Journal of Human Genetics 91, 998–1010, DecemUbe3b/ mice also displayed reduced grip strength
(Figure 6A), possibly reflecting central or muscular hypo-
tonia. Additionally, we observed reduced low-density
lipoprotein (LDL) levels in mutants (Figure 6B) and a trend
toward reduced total and HDL cholesterol levels (data not
shown). Notably, mass spectrometry-based analysis of
mouse plasma samples showed a significant reduction
of total cholesterol and lathosterol in Ube3b/ versus
WT mice, recapitulating the cholesterol findings in
the affected individuals. Mean total cholesterol was
1,642 mg/ml (range 744–2,633) in WT mice (n ¼ 12),
whereas it was 491 mg/ml (range 338–593) in Ube3b/
mice (n ¼ 5; p ¼ 0.0004). The lathosterol/total sterol ratio
was significantly lower in Ube3b/ mice (0.025) than in
WT mice (0.033; p ¼ 0.045).
In addition, homozygotes showed mild hearing impair-
ment (Figures 6C and 6D), in line with previous reports
of variable degrees of hearing impairment in Ohdo-like
BMR syndromes.17 We detected no gross inner ear malfor-
mations or signs of middle ear inflammation (data not
shown). Scanning electron microscopy of the organ of
Corti also showed no obvious defect to account for the
mild hearing impairment observed (data not shown).
Finally, histopathological analysis of eye tissue sections re-
vealed that 2/4 Ube3b/ mice displayed acute inflamma-
tion, calcification, and dilated lymphovascular channels
of the cornea (Figure S6D). Thus, Ube3b/ mice pheno-
copy the UBE3B-deficient BPID syndrome in several key
aspects, namely anomalies of body and brain size, weight,
muscular strength, and cholesterol levels.Discussion
Exome sequencing has greatly accelerated the identifica-
tion of causative mutations and novel disease-associated
genes in monogenic disorders.35 It can be combined with
linkage analysis in autosomal-dominant, autosomal-reces-
sive, and X-linked disorders or it can be performed in
affected children and their unaffected parents in cases of
sporadic disease caused by de novo mutations. However,
even with these strategies aiming at reducing the number
of candidate mutations, the analysis of exome-sequencing
data remains challenging because of the sheer number of
sequence variants identified. We have applied a stringent
filtering strategy that takes advantage of pedigree informa-
tion. Indeed, filtering for homozygous variants located in
larger homozygous stretches in the exome of the affected
child born to consanguineous parents and for possible
compound heterozygous mutations in the same gene in
the family in which the parents were unrelated left us
with a single candidate gene, thereby greatly reducing
the need for follow-up sequencing studies. Although this
filtering strategy critically depended on the genetic homo-
geneity of the disorder, it is applicable to other recessive
disorders, particularly when few patients are available for
analysis.ber 7, 2012
Figure 5. Reduced Growth of Ube3b
Mutant Mice
(A) Homozygous Ube3b/ mice (Hom)
show a significantly reduced growth
rate (weight curve comparison wild-type
[WT] versus Hom: p < 0.001) than WT or
heterozygote (Het) controls. The data are
presented relative to a reference range
that encompasses 95% of the natural vari-
ation, shown as the green shaded area,
constructed with 134 WT mice from
a variety of genetic backgrounds. Error
bars represent SD.
(B) A representative Ube3b/ mouse is
smaller and thinner than a WT control.
(C and D) A significantly reduced brain
section area (C) and a smaller hippocampus
area (D) are also evident. *p ¼ 0.0151,
**p ¼ 0.0049. Error bars represent SEM.Furthermore, our study illustrates the power of
combining results from exome sequencing with the gener-
ation and phenotypic analysis of a mouse model. For
example, observation of low cholesterol levels in two out
of three affected individuals might have been attributed
to chance or to dietary rather than genetic reasons.
However, significantly reduced cholesterol levels in
Ube3b/ mice seem to argue in favor of an underlying
defect in cholesterol metabolism. Our biochemical anal-
yses in patients and mice have indeed consistently
confirmed hypocholesterolemia and revealed low levels
of cholesterol precursors. Because individuals with low die-
tary intake or increased intestinal loss of cholesterol have
increased levels of cholesterol precursors, including lathos-
terol (unlike the affected individuals and mice reported
here), the observed hypocholesterolemia is more probably
due to decreased cholesterol synthesis. Ube3b has no
recognized function in cholesterol synthesis, and low
cholesterol levels in humans and mice deficient for Ube3b
might be an indirect consequence of altered ubiquitination
and degradation of cholesterol-metabolizing enzymes.
Although the exact mechanism underlying the observed
downregulation of cholesterol synthesis is unknown, the
observation of altered cholesterol metabolism in a novel
ID syndrome is interesting by itself. As a crucial component
of membranes, cholesterol is a constituent of myelin
sheaths and lipid rafts in neurons and astrocytes. Because
circulating cholesterol derived fromdietaryuptake and liver
synthesis cannot cross the blood-brain barrier, the brain is
dependent on cholesterol synthesis of astrocytes and—to
a lesser extent—neurons, making it particularly vulnerableThe American Journal of Human Genetito cholesterol deficiency.36 This
vulnerability is paradigmatically
illustrated in Smith-Lemli-Opitz syn-
drome (SLOS; MIM 270400), a
clinically distinct autosomal-recessive
neurodevelopmental disorder char-
acterized by growth retardation,
microcephaly, ID, and multiple mal-formations.37 SLOS is caused by deficiency of the enzyme
7-dehydrocholesterol reductase, which catalyzes the final
step of cholesterol biosynthesis. Although SLOS and the
UBE3B-deficient BPID syndrome share some rather unspe-
cific features such as growth retardation, microcephaly,
ptosis, and ID, it is evident from a clinical, dysmorphologi-
cal, and biochemical point of view that they represent
distinct disorders and that most probably there is no direct
overlap in their molecular pathophysiology.
In addition to the well-known involvement in neurode-
velopment, defects in protein degradation and ubiquitina-
tion have also been implicated in the pathogenesis of
neurodegenerative conditions such as Alzheimer and
Parkinson disease and amyotrophic lateral sclerosis.38
Furthermore, recent large-scale genome-wide studies of
copy-number variations have implicated gene networks
of neuronal cell adhesion and ubiquitination in the path-
ogenesis of autism.39 A homozygous p.Arg922Cys variant
in the HECT domain of UBE3B (annotated as p.Arg40Cys
by the authors with reference to a shorter transcript)40
was recently found to cosegregate with autism in a small
family, but the pathogenicity of this variant and the
possible clinical overlap with the BPID syndrome we
describe are currently unknown.40 The study of mono-
genic disorders has shed additional light on the role of
ubiquitination in the development and function of the
central nervous system. Whereas alterations of the im-
printed UBE3A gene cause Angelman syndrome, muta-
tions of UBE2A (MIM 312180; encoding an E2 enzyme)
and HUWE1 (MIM 300697; encoding a HECT domain E3
ligase)41 cause X-linked ID.42,43 The identification ofcs 91, 998–1010, December 7, 2012 1007
Figure 6. Neurosensory Abnormalities in
Ube3b/ Mice
(A and B) Ube3b/ mice show reduced grip
strength (A; p < 0.0001 WT versus Hom),
and low serum low density lipoprotein
(LDL) levels were also observed (B; p <
0.0001 WT versus Hom). The data are pre-
sented relative to a reference range that
encompasses 95% of the natural variation,
shown as the green shaded area, con-
structed with 132 (A) and 93 (B) WT mice
from a variety of genetic backgrounds.
Data are shown both as individual data
points and as a five point box plot
summary that indicates the median, first
and third quartiles (box), and minimum
and maximum values (whiskers).
(C and D) Auditory brainstem response
(ABR) thresholds (5SEM) were signifi-
cantly elevated in homozygotes (red)
compared with heterozygotes (blue) and
WT (green) littermates at 3 months (C)
and at 6 months (D) (mean elevations
cf. wild-types 15.0 5 3.5 dB, Q ¼ 4.427,
p < 0.05 at 3 months; 22.8 5 5.4 dB,
Q ¼ 4.671, p < 0.05 at 6 months).mutations of UBE3B in a complex BMR syndrome
comprising ID and multiple congenital anomalies further
supports the proposed pivotal role of UPS-mediated
protein degradation in organogenesis and in the devel-
oping central nervous system. The substrate specificity
and biological function of UBE3B are currently unknown,
but we have shown that its probable C. elegans ortholog
is indeed involved in UPS-mediated protein degradation.
It has long been debated whether reactive oxygen
species generated by oxidative stress are a cause or a conse-
quence of neurodegenerative diseases.44 Oxidative stress
can cause protein damage and mitochondrial dysfunction
and ultimately result in cell death. Our in vivo studies
in C. elegans suggest that UBE3B orthologs are particularly
important in the UPS under oxidative stress conditions.
Thus, neuronal dysfunction associated with UBE3B defi-
ciencymight be a consequence of a genetically determined
vulnerability toward oxidative stress.
Future studies will be directed at identifying the response
to oxidative stress and the ubiquitination targets of Ube3b,
particularly in the brain. The identification of target
proteins of individual ubiquitin ligases is experimentally
challenging, but recent large-scale approaches have re-
vealed hundreds of ubiquitination substrates and thereby
contributed to a better understanding of the regulation
of the proteome.45 The closest UBE3B paralog, UBE3C, is
associated with the human 26S proteasome through its N
terminus46,47 and is enriched in the human postsynaptic
density proteome,48 members of which are highly associ-
ated with ID. These data further link ubiquitin ligases to
cognitive function in humans.
Taken together, our results implicate biallelic UBE3B
loss-of-function mutations in a syndromic form of ID1008 The American Journal of Human Genetics 91, 998–1010, Decemand Ube3b deficiency in multiple anomalies in the mouse
and open up new research avenues into the complex
contribution of ubiquitination and oxidative stress to
mammalian neurodevelopment and brain function.Supplemental Data
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